Coronavirus (COVID-19) and Prostate Cancer
Updated: Nov 21, 2020
For 'Low' and 'Intermediate' risk prostate cancer, surveillance is being offered. In certain circumstances following a discussion at the multi-disciplinary team meeting, Intermediate risk prostate cancer patients have been offered 'Anti Androgens'. A database is being maintained to keep track of all patients on the modified pathway.